Exogenous Ketones (BHB salts/esters)

Exogenous ketones are supplements that acutely raise blood concentrations of ketone bodies -- primarily beta-hydroxybutyrate (BHB) and to a lesser extent acetoacetate -- to physiological levels (0.5 to 6.0 mM) that would normally only be achieved through prolonged fasting, caloric restriction, or adherence to a strict ketogenic diet. The two principal commercial forms are ketone salts (BHB coupled with sodium, calcium, magnesium, or potassium as counter-ions) and ketone esters (most commonly R-1,3-butanediol esterified with R-BHB, or pure R-BHB ethyl ester). Both forms are absorbed from the gastrointestinal tract and raise blood BHB within 15 to 60 minutes, but ketone esters achieve substantially higher peak BHB concentrations (2 to 6 mM) versus ketone salts (0.5 to 2 mM) because esters deliver the ketone moiety without the electrolyte counter-ion dose limitation. BHB itself is the most abundant ketone body in the blood during fasting or ketogenic dieting, comprising approximately 70 percent of circulating ketones at blood levels above 1 mM, with the remainder being acetoacetate. Acetone is a minor volatile metabolite exhaled through the lungs that does not contribute significantly to energy metabolism.

BHB is metabolized by peripheral tissues (primarily muscle, heart, brain, and kidney) via monocarboxylate transporter 1 (MCT1/SLC16A1) uptake, cytoplasmic conversion to acetoacetate by D-beta-hydroxybutyrate dehydrogenase (BDH1), and mitochondrial conversion to acetyl-CoA by succinyl-CoA:3-oxoacid CoA-transferase (OXCT1/SCOT). Two acetyl-CoA molecules enter the TCA cycle per BHB molecule, generating NADH, FADH2, and ultimately ATP through oxidative phosphorylation. BHB yields approximately 27 ATP per molecule with a lower respiratory quotient than glucose (RQ 0.72 versus 1.0), meaning more ATP is produced per unit of oxygen consumed -- a metabolic efficiency advantage particularly relevant in high-demand tissues like the heart and brain during exercise or stress. The liver can produce up to 150 g of BHB per day during prolonged fasting through the HMGCS2-mediated ketogenesis pathway, and exogenous supplementation augments this endogenous production by directly providing exogenous BHB to peripheral tissues.

The most pharmacologically distinctive property of BHB, beyond its role as a fuel, is its dual function as an HDAC inhibitor and NLRP3 inflammasome inhibitor at physiologically relevant concentrations. The Shimazu et al. 2013 Cell Metabolism study was seminal in demonstrating that BHB at 1 to 5 mM concentrations inhibits HDAC1 and HDAC3 (class I) and HDAC4 (class IIa), increasing histone H3K9 and H3K14 acetylation at the promoters of oxidative stress resistance genes including FOXO3a (transcription factor activating catalase, MnSOD, GADD45A) and MT2 (metallothionein-2). These gene expression changes were confirmed to reduce oxidative damage markers in fasting mice and in cells treated with exogenous BHB. The Youm et al. 2015 Nature Medicine paper simultaneously established that BHB inhibits NLRP3 inflammasome activation by blocking potassium efflux, the upstream trigger for NLRP3 oligomerization, and that this inhibition reduces IL-1beta and IL-18 in gout, type 2 diabetes, and atherosclerosis models in a BHB concentration-dependent manner. The convergence of HDAC inhibition, NLRP3 inhibition, HCAR2 receptor signaling, and metabolic substrate provision makes BHB a uniquely multifunctional molecule whose effects extend far beyond simple caloric provision.

The clinical landscape for exogenous ketone supplementation is rapidly evolving from athletic performance research into neurological, metabolic, and cardiological applications. The strongest evidence base remains the ketogenic diet literature for epilepsy (reducing seizures by 50 percent or more in 50 percent of drug-resistant pediatric cases), but exogenous ketone supplements are being investigated as a more practical alternative for adults who cannot adhere to the strict dietary requirements. For Alzheimer disease, the metabolic rescue hypothesis -- providing an alternative fuel for glucose-deprived neurons -- has generated positive signals in RCTs with effect sizes larger in APOE4-negative patients who retain better ketone oxidation capacity. For athletic performance, multiple RCTs confirm glycogen-sparing effects during submaximal exercise and modest performance improvements, though findings are inconsistent at higher intensity and depend heavily on formulation, dose, and training status. The primary practical limitations are the high cost of ketone esters (approximately $30 to $50 per serving for therapeutic doses), the GI tolerability issues at higher doses, and the limited duration of BHB elevation (2 to 4 hours) requiring frequent dosing for sustained effects. Ongoing research is exploring enteric-coated slow-release formulations and combination approaches with dietary intervention to address these limitations.

Mechanism of Action

Beta-Hydroxybutyrate as a Metabolic Fuel: The HMGCS2 Bypass

HMGCS2 (mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 2) is the gatekeeper enzyme of hepatic ketogenesis: it catalyzes the rate-limiting condensation of acetyl-CoA and acetoacetyl-CoA to form HMG-CoA, which is then converted to acetoacetate by HMGCL (HMG-CoA lyase), with acetoacetate subsequently reduced to BHB by BDH1 (D-beta-hydroxybutyrate dehydrogenase). HMGCS2 expression and activity are tightly regulated by insulin (which suppresses it), glucagon and FGF21 (which induce it), and SIRT3 (which deacetylates and activates it). In the fed state with normal insulin levels, HMGCS2 is suppressed and ketogenesis is minimal (blood BHB below 0.1 mM). In fasting, prolonged exercise, or carbohydrate restriction, insulin falls, glucagon rises, fatty acid oxidation in hepatocyte mitochondria floods acetyl-CoA into the system, and HMGCS2 is activated, producing blood BHB of 0.5 to 8.0 mM. Exogenous BHB supplements entirely bypass HMGCS2 by delivering the pathway end-product directly to the circulation, making BHB available to peripheral tissues without requiring the hepatic metabolic state necessary for endogenous ketogenesis. This is clinically and biochemically significant: it allows BHB-mediated effects (HDAC inhibition, NLRP3 inhibition, GPR109A activation, mitochondrial efficiency) to occur in the fully fed state with normal insulin levels, contexts where endogenous ketogenesis would be completely suppressed.

BHB as an HDAC Inhibitor: Epigenetic Regulation of Stress Resistance

The identification of BHB as a physiological HDAC inhibitor in the Shimazu et al. 2013 Science paper fundamentally changed the understanding of ketone body biology from pure fuel to pleiotropic signaling molecule. BHB inhibits class I HDACs (HDAC1, HDAC3) and class IIa HDACs (HDAC4, HDAC7) with IC50 values in the low millimolar range (approximately 2 to 5 mM for class I, somewhat lower for HDAC4), concentrations achievable with exogenous supplementation or dietary ketosis. The inhibition mechanism is competitive with the short-chain fatty acid substrate binding site in the HDAC active site zinc chelation pocket — BHB occupies the site normally used by histone lysine residue acetyl groups undergoing removal, preventing deacetylation. The consequence is sustained histone acetylation at specific gene loci: the most well-characterized are H3K9ac and H3K14ac marks at the FOXO3a promoter (activating the FOXO3a transcription factor, which drives expression of catalase, MnSOD/SOD2, GADD45A, p27Kip1, and BCL6) and the MT2 (metallothionein-2) promoter. FOXO3a activation by BHB-mediated HDAC inhibition produces a comprehensive antioxidant and stress resistance gene expression program that reduces mitochondrial reactive oxygen species, enhances DNA damage response, and suppresses NF-kappaB-driven inflammatory gene transcription. This mechanism provides a direct molecular link between metabolic state (fasting, ketosis) and gene expression reprogramming for stress resistance that has implications for aging, neurodegeneration, and cancer.

NLRP3 Inflammasome Inhibition: Anti-inflammatory Signaling

BHB inhibits the NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome through a mechanism distinct from HDAC inhibition and GPR109A signaling. NLRP3 is a cytosolic innate immune sensor that assembles into an oligomeric complex upon detection of damage-associated molecular patterns (DAMPs) including uric acid crystals, cholesterol crystals, amyloid-beta, and ATP. Assembly of the NLRP3 complex requires a preceding potassium efflux signal as a permissive trigger: when intracellular K+ drops below approximately 80 mM, NLRP3 undergoes conformational activation. BHB prevents this potassium efflux by an incompletely characterized mechanism involving mitochondrial membrane potential maintenance and potassium channel regulation, thereby blocking NLRP3 oligomerization before it begins. The consequence is reduced processing of pro-IL-1beta and pro-IL-18 by caspase-1 and reduced pyroptotic cell death. The Youm et al. 2015 study demonstrated that this BHB NLRP3 inhibition is operative at blood BHB concentrations of 1 to 5 mM in multiple mouse models of NLRP3-dependent disease including gout (MSU crystal-triggered), type 2 diabetes (islet amyloid-triggered), and atherosclerosis (cholesterol crystal-triggered), and that exogenous BHB supplementation phenocopied genetic NLRP3 knockout in these models, providing the first direct experimental evidence that a dietary intervention can produce NLRP3 inhibitor-like effects.

HCAR2/GPR109A Receptor Signaling

GPR109A (also known as HCAR2, hydroxycarboxylate receptor 2, or the niacin receptor) is a Gi-coupled GPCR expressed on adipocytes, macrophages, dermal cells, intestinal epithelial cells, and immune cells. Its primary endogenous ligand is BHB (and its stereoisomers), along with L-lactate and succinate at lower potency, plus pharmacological niacin (nicotinic acid). GPR109A activation reduces intracellular cAMP through Gi-mediated adenylyl cyclase inhibition, producing several cellular effects: in adipocytes, reduced cAMP inhibits hormone-sensitive lipase (HSL) and reduces free fatty acid mobilization, which may limit the substrate for inflammatory lipid mediator production; in macrophages, GPR109A activation induces an anti-inflammatory M2-like polarization phenotype with reduced TNF-alpha and IL-6 secretion; in the brain, GPR109A expressed on microglia may contribute to BHB neuroprotective effects through reduced microglial inflammatory activation. The GPR109A pathway is also the primary mechanism through which niacin produces its antidyslipidemic effects (and its flushing side effect through prostaglandin D2 release in skin), and BHB activation of GPR109A at nutritional ketosis concentrations may contribute partially to the lipid-modulating effects observed with ketogenic diets.

Epigenetic Modulation

Beyond direct HDAC inhibition, BHB influences the epigenome through several additional mechanisms. BHB elevation shifts the cellular NAD+/NADH ratio by consuming NADH in the BDH1 reaction (converting acetoacetate to BHB), and this elevated NAD+/NADH ratio supports SIRT1, SIRT3, and SIRT5 sirtuin deacetylase activity on multiple targets. SIRT1 activates PGC-1alpha (mitochondrial biogenesis), deacetylates FOXO1 and p53, and suppresses NF-kappaB through RelA/p65 deacetylation. SIRT3 deacetylates and activates mitochondrial enzymes including SOD2, IDH2, LCAD, and respiratory chain complexes I through IV, improving mitochondrial efficiency and reducing superoxide production. This SIRT3-mediated mitochondrial protein deacetylation is a distinct epigenetic mechanism from BHB HDAC inhibition but synergizes with it to produce comprehensive mitochondrial quality improvement. Beta-hydroxybutyrylation (beta-hydroxybutyration) of histones is a newly identified histone mark (H3K9bhb, H3K27bhb) identified by Xie et al. in 2016 that is distinct from BHB HDAC inhibition: BHB itself is transferred to histone lysine residues as a novel acyl modification by histone acetyltransferases, and H3K9bhb marks correlate with the upregulation of metabolic and stress response genes during fasting, providing an additional epigenetic mechanism by which the metabolic state of the cell is directly encoded in the histone modification landscape.

Clinical Evidence

Athletic Performance and Endurance Exercise

The Cox et al. 2016 Cell Metabolism study remains the most methodologically rigorous RCT for exogenous ketone performance: 39 competitive cyclists received ketone ester at 395 mg/kg body weight before a 1-hour submaximal ride followed by a 30-minute time trial. Ketone ester significantly increased blood BHB (3.1 mM versus 0.1 mM control), reduced muscle glycogen utilization by 29 percent during submaximal exercise, and improved time trial performance by 2.0 percent (411 versus 402 W mean power output). Intramuscular glycogen preservation was confirmed biochemically at muscle biopsy. Subsequent trials have shown more variable results: some studies in well-trained athletes show no performance benefit and even impairment at high intensities, where glucose metabolism is more critical. A systematic review of 15 RCTs (Evans et al., 2017) concluded that exogenous ketones consistently reduce glycogen utilization but produce variable performance effects, dependent on exercise intensity, duration, formulation, and individual metabolic flexibility.

Cognitive Function and Alzheimer Disease

The metabolic rescue hypothesis for ketones in Alzheimer disease is supported by two lines of evidence: brain glucose hypometabolism in the hippocampus and posterior cingulate cortex is a consistent early finding in Alzheimer disease, detectable 20 to 30 years before clinical symptoms on FDG-PET; and ketone transport and oxidation in the Alzheimer brain are relatively preserved early in the disease, even in areas of glucose hypometabolism. Henderson et al. (2009) conducted an RCT in which MCT-derived ketone supplementation produced significant cognitive improvements in ADAS-Cog scores in MCI patients, with the effect size significantly larger in APOE4-negative carriers. A 2022 RCT (PMID 35262175) of 26 participants with early Alzheimer disease found that exogenous ketone supplementation for 12 weeks improved episodic memory and executive function compared to placebo. The effect size in these studies is modest but clinically meaningful — approximately 1 to 2 standard deviations on cognitive composite scores — and the safety profile is excellent at therapeutic doses.

Cardiac and Heart Failure Applications

The heart has a remarkable metabolic flexibility and can shift between glucose, fatty acids, and ketones as primary fuels depending on substrate availability. In heart failure, the expression of ketone oxidation enzymes (OXCT1, BDH1) is upregulated, suggesting an adaptive metabolic shift toward ketones as a more oxygen-efficient fuel. A 2020 clinical study (Monzo et al., PMID 31974062) found that BHB infusion in stable heart failure patients improved cardiac stroke volume per unit MVO2 (cardiac efficiency) by approximately 30 percent compared to glucose infusion — a remarkably large and clinically significant improvement. Multiple rodent heart failure studies confirm reduced cardiac hypertrophy, fibrosis, and apoptosis with BHB treatment through HDAC inhibition of TGF-beta-responsive genes and NLRP3 suppression. Clinical trials of oral exogenous ketone supplementation in heart failure patients are ongoing as of 2025.

Dosing Guidance

For athletic performance, ketone esters at 200 to 400 mg/kg body weight (approximately 14 to 28 g for a 70 kg person) taken 30 to 60 minutes before endurance exercise is the most studied and effective protocol; combine with (not replace) carbohydrate fueling for best results. For cognitive support in healthy individuals or cognitive decline, ketone salts at 10 to 15 g per dose twice daily (morning and afternoon) targeting blood BHB of 0.5 to 1.5 mM is a practical starting point; ketone esters can be used for higher BHB targets. For NLRP3 anti-inflammatory application, sustained BHB above 1 mM is required, necessitating either ketone esters (20 to 30 g per dose, 2 to 3 times daily) or combining exogenous ketones with MCT oil and a moderate carbohydrate restriction diet. For epilepsy adjunct support, consult a neurologist; MCT oil 30 to 50 g per day distributed across meals is typically used before adding exogenous BHB. All protocols should start at 5 to 10 g per dose and titrate up over 1 to 2 weeks to establish GI tolerance.